This study is for older adults or those not fit for intense treatment, who have a type of blood cancer called acute myeloid leukemia (AML) with a FLT3 mutation (a change in the DNA of a gene involved in cell growth). It compares usual treatment with azacitidine and venetoclax to adding gilteritinib, another cancer-fighting drug. Azacitidine helps control cancer cell growth, venetoclax blocks a protein that helps cancer cells live, and gilteritinib stops cancer cells from multiplying. The study wants to see if the combination works better than the usual treatment.

Key Points:

• The study involves taking medicines in cycles, typically every 28 days, for up to 2 years.
• Participants will have regular check-ups, blood tests, and bone marrow exams to monitor progress.
• Eligibility includes being 60 years or older, or younger but unfit for strong treatment, and having specific genetic mutations.